Researchers find that pre-existing mutations can lead to drug resistance in HIV virus

June 7, 2012

In a critical step that may lead to more effective HIV treatments, Harvard scientists have found that, in a small number of HIV patients, pre-existing mutations in the virus can cause it to develop resistance to the drugs used to slow the progression of the disease.

The finding is particularly important because, while researchers have long known HIV can develop resistance to some drugs, it wasn't understood whether the relied on pre-existing mutations to develop the resistance, or if it has to wait for those mutations to occur. By shedding new light on how resistance evolves, the study, reported in online journal PLoS on June 7, opens the door to the development of new, more effective treatments.

"In order to prevent the of resistance, we need to know where the resistance mutations are coming from, it was exciting to realize data from could help us solve this puzzle," Pennings said. "If we understand how the virus develops resistance, we can think of new ways to prevent it."

In a study of data collected in 26 clinical trials, Pennings found that, in patients receiving treatment with a typical combination of non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs, the virus is more likely to develop resistance shortly after the start of treatment or when treatment is restarted following an interruption of a week or more, but less likely to develop resistance later on during treatment and when patients do not interrupt treatment.

It is that finding that pointed Pennings to the conclusion that pre-existing mutations were behind the virus' drug resistance. Researchers have shown in past studies that resistance that develops early in treatment is likely the result of pre-existing mutations. Resistance that develops later is tied to mutations in the virus that occur after treatment began.

Pennings also analyzed data from trials with who were treated with the drug nevirapine to prevent mother-to-child-transmission of the virus. Those trials show that the evolution of nevirapine resistance due to pre-existing mutations was reduced if the women were treated with the ZDV (often called AZT) prior to receiving . Among the possible reasons for the reduction is the fact that ZDV reduces the viral population, thereby reducing the number of pre-existing resistant viral particles in the patient.

Those findings, Pennings said, suggest that a similar approach, with some kind of pre-treatment, may be useful for all patients who start or restart NNRTI-based treatment.

While the study holds out hope for the future development of more effective , Pennings emphasized that data used in the study came from trials , which exclusively included patients receiving NNRTI or unboosted protease inhibitor treatments. It is unclear whether the results can be generalized to other treatments and to patients who are not enrolled in clinical trials.

"It has long been known that treatment interruptions can lead to , but it is also clear that in real life such interruptions cannot always be avoided," Penning said. "The good news is that there may be ways to prevent the evolution of resistance even if the patient interrupts treatment. Our results suggest that we need to focus on how patients reinitiate treatment after an interruption. I hope to find collaborators who are interested to test these ideas in clinical trials.

"It was great to see that models from evolutionary biology could be used to understand data from studies," she continued. "Once I had the data, it was surprisingly easy to find that resistance evolves due to pre-existing mutations in six percent of patients who start NNRTI based treatment. For the other 94 percent, , they have a risk of approximately two to three percent per year that resistance evolves. As an evolutionary biologist, I am excited to know these numbers, but the immediate next step is to think about how to reduce these numbers to zero."

Explore further: Drug designer: New tool reveals mutations that cause HIV-drug resistance

More information: Pennings PS (2012) Standing Genetic Variation and the Evolution of Drug Resistance in HIV. PLoS Comput Biol 8(6): e1002527. doi:10.1371/journal.pcbi.1002527

Related Stories

Drug designer: New tool reveals mutations that cause HIV-drug resistance

July 8, 2011
Protease inhibitor drugs are one of the major weapons in the fight against HIV, the virus that causes AIDS, but their effectiveness is limited as the virus mutates and develops resistance to the drugs over time. Now a new ...

Recommended for you

Study suggests a way to stop HIV in its tracks

December 1, 2017
When HIV-1 infects an immune cell, the virus travels to the nucleus so quickly there's not enough time to set off the cell's alarm system.

Discovery puts the brakes on HIV's ability to infect

November 30, 2017
Viewed with a microscope, the virus faintly resembles a pineapple—the universal symbol of welcome. But HIV, the virus that causes AIDS, is anything but that. It has claimed the lives of more than 35 million people so far.

Rising levels of HIV drug resistance

November 30, 2017
HIV drug resistance is approaching and exceeding 10% in people living with HIV who are about to initiate or reinitiate first-line antiretroviral therapy, according to the largest meta-analysis to date on HIV drug resistance, ...

Male circumcision and antiviral drugs appear to sharply reduce HIV infection rate

November 29, 2017
A steep drop in the local incidence of new HIV infections accompanied the rollout of a U.S.-funded anti-HIV program in a large East-African population, according to a study led by researchers at Johns Hopkins Bloomberg School ...

Combination HIV prevention reduces new infections by 42 percent in Ugandan district

November 29, 2017
A study published today in the New England Journal of Medicine provides real-world evidence that implementing a combination of proven HIV prevention measures across communities can substantially reduce new HIV infections ...

Research on HIV viral load urges updates to WHO therapy guidelines

November 24, 2017
A large cohort study in South Africa has revealed that that low-level viraemia (LLV) in HIV-positive patients who are receiving antiretroviral treatment (ART) is an important risk factor for treatment failure.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.